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In the preterm born population, late-onset sepsis (LOS) continues to have a 
significant impact on morbidity and mortality, length of hospital admission and 
economic costs [1]. Extremely preterm infants (gestational age <28 weeks) have an 
increased infection risk due to a naive immune system and the almost universal 
requirement of invasive procedures such as intravascular catheter placement [2]. 
Although disruption of the skin by invasive procedures increases the risk of LOS 
development, bacterial translocation from the intestine may also be an important 
pathway initiating LOS in extremely preterm infants [3]. This is based on the various 
observations that microbial intestinal dysbiosis precedes clinical onset of LOS [4-14]. 
An immature intestinal epithelial barrier function [15], low intestinal motility, scanty 
mucus flow and reduced enteric production of antimicrobial factors [16], combined 
with microbial dysbiosis, may induce an inflammatory process affecting the mucosal 
integrity by loss of mucosal tight junctions [17]. An impaired intestinal integrity could 
provoke transmucosal translocation of gut microbes resulting in bacteremia and 
eventually LOS [18 19]. In recent studies, we have observed that fecal volatile 
organic compound (VOC) profiles from preterm infants developing LOS differed from 
the profiles from strictly matched controls, already up to three days prior to clinical 
onset [20 21]. Since fecal VOCs, referred to as the odorous fecal fingerprint, are 
considered to reflect microbiota composition, metabolic activity and the interaction 
between microbiota and the host [22], fecal VOC composition analysis may be useful 
as an early, non-invasive diagnostic biomarker for LOS. These observed alterations 
in fecal VOC profiles increases the plausibility of the involvement of the intestinal 
microbiota in LOS pathogenesis. However, in these VOC studies, vast majority of 
LOS cases had a central venous catheter CVC during LOS development, and this 
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variable should obviously be acknowledged. Although observed early alterations in 
fecal VOC profiles may reflect disturbance of gut microbiota composition, in infants 
with a central line-associated blood stream infection (CLABSI) these VOC differences 
may also result from a systemic inflammatory response rather than caused by 
alterations in microbiota composition. Therefore, to increase knowledge about the 
origin of fecal VOCs in preterm infants developing LOS, we investigated fecal VOC 
profiles of infants with non-CLABSI. Primary involvement of the gut in LOS 
pathophysiology may in future allow for the development of novel (microbiota-based) 
interventions aimed at the prevention of LOS in the preterm born population.   
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Materials and Methods 
Subjects 
Between October 2014 and August 2016, preterm infants born at a gestation of ≤30 
weeks were recruited to participate in this prospective cohort study performed at 
eight neonatal intensive care units (NICU) in the Netherlands and Belgium. Infants 
born with congenital gastrointestinal anomalies, receiving gastrointestinal surgery or 
developing either spontaneous intestinal perforation (SIP) or necrotizing enterocolitis 
(NEC) (Bells stage ≥IIA) within the first 28 days were excluded from further 
participation. In this ongoing study, fecal samples are collected daily from the diaper 
up to the 28th day postnatally. Probiotics were not administered routinely in any 
participating NICU. Written informed consent was obtained from all parents of 
included patients. This study was approved by local Institutional Review Boards of all 
participating medical centers. 
Infants were allocated to the LOS group when all three Vermont Oxford criteria [23] 
for LOS were met; (1) presence of at least one clinical sign of generalized infection; 
(2) isolation of a bacterial pathogen or a Coagulase-negative Staphylococcus (CoNS) 
from at least one blood culture obtained ≥ 72 hours after birth; and (3) administration 
of adequate intravenous antibiotic regimen directed to this specific pathogen for a 
minimum of five days. Septic infants with an umbilical venous catheter, umbilical 
arterial catheter and those with a peripherally inserted central catheter within 48 
hours prior to the onset of LOS, thereby meeting the criteria for CLABSI [24], were 
excluded. Infants without congenital gastrointestinal anomalies, not receiving 
gastrointestinal surgery or developing early-onset sepsis, LOS, SIP or NEC during 
their first 28 postnatal days were eligible to be included as control infant. For a more 
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detailed description we refer to previously conducted studies and the supplemental 
content (Supplemental Methods) [20 21].  
Sample selection 
Fecal samples produced at one (t-1), two (t-2) and three (t -3) days prior to clinical onset 
of LOS (t0), were selected for VOC analysis, since previous studies demonstrated 
differences in fecal VOC profiles up to three days prior to LOS onset [20 21]. Each 
fecal sample from infants allocated to the LOS group was strictly matched to one 
fecal sample from a control, based on (1) center of birth, (2) gestational age, (3) 
birthweight, (4) postnatal age on the day of sample collection, (5) enteral feeding 
pattern (proportion breastmilk/formula) and (6) cumulative number of days exposed 
to administered antibiotics prior to t0. 
VOC measurements  
Fecal VOC analysis was performed by Field Asymmetric Ion Mobility Spectroscopy 
(FAIMS) (Lonestar®, Owlstone, Cambridge, England). In Lonestar®, provided VOCs 
are first ionized by a NI-63 radiation source before being transported further using a 
carrier gas. Subsequently, these ionized molecules enter an asymmetric electrical 
field towards a detector plate while simultaneously passing two metal plates. The 
applied voltage (dispersion field (DF)) alternates between prolonged low electrical 
voltages and short high voltages, causing the ionized molecules to move in a ion-
specific ‘tooth saw-like’ pattern. Since these ions lose their electrical charge after 
touching one of the metal plates, a compensation voltage (CV) is applied, preventing 
ions to be left undetected by the detector plate [25]. In summary, ions in a complex 
gaseous mixture could be separated based on ion-specific mobility differences by 
stepwise altering the DF and CV ultimately allowing for 52.224 data points [26]. For a 
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more detailed description of a FAIMS measurement we refer to the supplemental 
content (Supplemental Methods). 
Data analysis 
All of the analysis was performed using R version 3.4.1. Independent t test and chi-
square test were applied for comparison of basic demographics and clinical 
characteristics between the two study groups. A p-value of less than 0.05 was 
considered statistically significant. The eNose data was analyzed using a previously 
developed pipeline [21 27]. In short, the Lonestar® was configured to generate a 2D 
matrix of 52.224 data points per sample. Each sample was pre-processed by 
applying a 2D discrete wavelet transform (Daubechies D4) (wavethresh R package) 
to compress the data and extract subtle chemical signals. Once completed, a 
threshold was applied to the standard deviation of the features, removing those 
features that vary by only a very small amount (or not at all). A 10 fold cross-
validation was then used, with 90% of the data as a training set and the remaining 
10% as a test set. Within each fold, supervised feature selection and classification 
models were performed. For this, Wilcoxon rank sum test was used on the training 
set to calculate the p-value for each feature, then keeping only the features with the 
lowest p-value after applying Bonferroni correction. The selected features then used 
as an input to train the classification models. Finally, five different classification 
algorithms were used to produce the class predictions. They were Sparse Logistic 
Regression (glmnet R package), Gaussian Process Classifier (kernlab R package), 
Random Forest (randomForest R package), Support Vector Machine (kernlab R 
package), and Neural Network (neuralnet R packega). The receiver operating 
characteristic (ROC) curves with corresponding sensitivity, specificity, positive 
predictive value and negative predictive value were produced for each classification 
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model. This was undertaken as it has been observed that one or more algorithm will 
be better suited to a given task and by evaluating a number of these algorithms 
allows for identification which is best for this task. Cronbach’s alpha was calculated to 
demonstrate any consistency between the VOC profiles.  
Fecal VOC profiles from infants with non-CLABSI were compared with VOC profiles 
from strictly matched controls at one (t-1), two (t-2) and three (t -3) days prior to clinical 
onset of the disease. To assess the potential of fecal volatiles as early biomarker for 
LOS in clinical practice, regardless of the number of days prior to clinical onset that 
the last fecal sample was produced, only the last fecal sample available prior to LOS 
onset was used from all cases in an additional analysis. Since each bacterial species 
produces a species-specific VOC profile [28], VOCs deriving from fecal samples 
closest to t0 from infants with LOS caused by similar species (CoNS and 
Staphylococcus epidermidis) were compared with controls. To limit the influence of 
center-specific differences in VOC outcome due to local protocols, such as 
differences in feeding pattern and in administered antibiotic types, VOC profiles of 
infants with and without LOS from the same center of origin were compared in an 





In total, 591 preterm infants were included during the study period, of whom 169 
(28,6%) developed LOS within the first 28 postnatal days (Supplemental Table S1). 
Ultimately, samples from 24 infants with non-CLABSI could be strictly matched to 
controls and were selected for fecal VOC analysis (Figure 1). Patient characteristics 
of these 24 LOS infants and their matched controls are depicted in Table 1. In fifteen 
infants (63%), a CoNS was isolated from the blood culture (Table 2).  
Fecal volatile organic compound analysis 
Per individual analysis, data of the best performing classification model is shown in 
Table 3, while in Supplemental Table S2, a complete overview is given of the data 
generated by all five classification models. Up to three days prior to clinical sepsis 
onset, fecal VOC profiles differed between cases and controls, corresponding area 
under the curve (AUC) [±95% confidence interval], sensitivity and specificity at t-3 
(0.78 [0.62-0.93], 0.82, 0.65), at t-2 (0.65 [0.46-0.85], 0.59, 0.82) and t-1 (0.78 [0.63-
0.94], 0.61, 0.83). Differences were statistically significant at t-3 (p-value = 0.002) and 
t-1 (p-value = 0.001), but not at t-2 (p-value = 0.061). 
Discriminative accuracy increased after selection of the last produced fecal sample 
prior to t0 of LOS cases with a CoNS species as causative agent (0.79 [0.62-0.95], 
0.87, 0.67). This accuracy augmented even further after only selecting LOS cases 
caused by Staphylococcus epidermidis (0.95 [0.86-1], 1, 0.83) (Table 3, Figure 2). 
Fecal volatile profiles of LOS cases originating from the NICU with the largest group 
of LOS cases, irrespective of isolated pathogen (n=9) (referred to as Centre 1), could 
be statistically significantly discriminated from matched controls of the same center 
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(0.95 [0.86-1],1, 0.78) (Table 3). Cronbach’s alpha, a measure of internal 
consistency, was calculated to be 0.98 at each individual time-point, indicating a high 





In this study, we demonstrated that fecal VOC profiles allowed for the discrimination 
between preterm infants developing non-catheter related LOS and matched controls, 
up to three days prior to clinical onset of LOS. Discriminative accuracy increased 
upon performing subgroup analysis on VOC profiles of LOS cases caused by the 
same bacterial species. 
Two previous studies have attempted to discriminate LOS cases from controls by 
fecal VOC profiling [20 21]. In the first study, performed at three NICUs and including 
36 LOS cases, affected subjects could be differentiated from controls at three, two 
and one day prior to clinical sepsis onset with only modest accuracy; 58.8%, 72.7% 
and 64.3% respectively [20]. The higher discriminative performance observed in the 
present study may potentially be explained by the exclusion of patients with an 
indwelling CVC. By excluding infants with a CLABSI, the number of LOS cases 
resulting from skin invasive procedures remained limited, simultaneously increasing 
the plausibility of a gut-derived sepsis. Hypothetically, uniform alterations in gut 
microbiota composition preceding LOS onset may have resulted in the increased 
discriminative accuracy observed in the current study. Another potential explanation 
is the use of a different eNose device. Whereas the currently applied eNose 
(Lonestar®) generates 52.224 individual data points, the previously applied 
Cyranose320 only allows for 32 data points [26 29].  
In the second study, including 127 LOS cases from nine different NICUs, highest 
discriminative accuracies were obtained in the subgroup analyses including LOS 
cases with the same bacterial species obtained from blood culture. In the subanalysis 
including cases with a Staphylococcus epidermidis sepsis, fecal VOCs allowed for 
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discrimination at day 1, 2 and 3 days prior to LOS onset. Focusing on the fecal VOC 
profile of the last sample obtained prior LOS onset from all Staphylococcus 
epidermidis cases resulted in a non-statistically significant discrimination between 
cases and controls with a corresponding AUC of 0.63, whereas the AUC obtained in 
the current study was 0.95. We hypothesize that this difference can at least partly be 
attributed to the exclusion of central-line associated LOS cases in the current study. 
By excluding infants meeting the criteria for CLABSI, the number of LOS cases 
caused by a pathogen originating from skin invasive procedures instead of intestinal 
bacterial translocation remained limited. In particularly bacteria belonging to the 
CoNS, including Staphylococcus epidermidis, may extensively be found on the skin 
[30] and are often associated with CLABSI. In LOS cases where the pathogen 
originates from the skin and not from the intestines, fecal VOC profiles may not have 
been altered in a preclinical stage, hampering the ability to discriminate between 
cases and controls based on these profiles.  
As demonstrated in previous studies, LOS onset by CoNS may be preceded by an 
intestinal increase in abundance of CoNS species [9 12]. This may presumably 
explain the high discriminative accuracy to differentiate between CoNS sepsis and 
control infants in the present study. However, in contrast to the current study, fecal 
VOCs did not allow for discrimination between cases with a CoNS sepsis and 
controls in the previous study [21]. We hypothesize that this apparent discrepancy 
may not only be explained by the exclusion of central line-associated LOS cases, but 
also by the presence of a more homogeneous group CoNS pathogens in the current 
study. In this study, Staphylococcus epidermidis comprised 80% of the isolated 
CoNS pathogens, whereas they only accounted for 58% of the CoNS pathogens in 
the previous study. Different bacterial species produce a unique metabolic fingerprint 
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and provoke a unique host-pathogen interaction [28 31]. The more homogenous 
group of CoNS LOS cases in this study may therefore have generated a more 
clustered VOC cloud and consequently higher discriminative accuracy to differentiate 
between CoNS cases and controls. 
Since VOCs are produced during (patho)physiological metabolic processes, CLABSI 
could hypothetically induce a systemic metabolic response, leading to (secondary) 
changes of fecal VOCs. Our observation that in septic preterm infants without a CVC 
fecal VOCs differed from controls suggests that, at least in this population, the gut 
microbiota may play a pivotal role in LOS pathogenesis, rather than being a 
secondary phenomenon. This concept has already been advocated by the findings of 
Lepainteur and colleagues, who compared DNA from blood cultures with 
corresponding DNA of CVC in infants with CLABSI, and concluded that CVC as 
origin of sepsis could be questioned in up to 70% of the cases [7]. 
Notably, two days prior to clinical LOS onset, fecal VOCs did not allow statistically 
significant discrimination between LOS and controls (p-value = 0.06). Possible 
explanations are the relatively small sample size and substantial differences in center 
of birth and clinical characteristics of LOS subjects. The influence of environmental 
factors on fecal VOC composition, including center of origin [32], has been described 
previously, possibly resulting from differences in center-specific feeding patterns, 
medication usage, and bacterial exposure. In contrast to chemical analytical 
techniques such as gas chromatography-mass spectrometry (GC-MS), an eNose 
such as Lonestar®, with a sensing method mimicking the olfactory system, does not 
allow for identification of individual volatile compounds [33]. Confounding VOCs 
originating from non-avoidable and non-relevant environmental and sampling 
sources, like those deriving from antibiotics, may have significantly influenced eNose 
 
14 
results[32]. Consequently, this may negatively influence discriminative accuracy. The 
influence of inter-center variation in VOC outcome is illustrated by the increased 
accuracy for sample classification in the sub-analysis including only infants born at 
one center. 
It the present study, multiple prediction models were selected. Since performance of 
the various models demonstrate considerable variation, it is questioned whether a 
certain classifier model may have universal applicability in different populations [21 
34]. Future studies should focus on assessing which model provides optimal 
accuracy in various clinical and research settings. 
Strengths of this study are the prospective multicenter design with strict sampling and 
detailed data collection allowing the stringent matching of cases and controls based 
on clinical and demographic characteristics. In contrast, we also acknowledge 
several limitations, including the relatively small contribution of non-CLABSI to the 
total number of LOS cases in this cohort. Another limitation is the relatively small 
number of LOS cases caused by Gram-negative pathogens, although the proportion 
(about 20%) of total LOS was comparable to other studies [2 35]. Furthermore, other 
possible routes of LOS acquisition, like peripheral inserted infusions and invasive 
respiratory procedures, could not be corrected for due to the limited sample size. 
Lastly, although current study outcomes increase the plausibility of the involvement of 
gut microbes in the etiology of LOS in preterm infants, concurrent analysis of the 
microbiota composition could add understanding on the detected differences in fecal 
VOCs.  
Future studies are needed to externally validate our findings, preferably in larger 
cohorts. Prior to implementation of eNose technology in clinical practice to predict 
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LOS in an early stage, identification of LOS-specific and ideally species-specific 
VOCs, by techniques such as gas chromatography-mass spectrometry (GC-MS), is 
required for the development of a tailor-made eNose. Chemical analytical techniques 
including GC-MS are relatively expensive, time-consuming and not applicable in daily 
clinical practice, but are inevitable for the development of a primed eNose for LOS-
related VOCs, applicable in a clinical setting. Primed eNose sensors may allow for 
targeted VOC detection, not influenced by non-relevant environmental factors, 
resulting in an optimal discriminative accuracy under non-standardized conditions, 
consequently providing opportunities for development of interventions aimed at 
prevention of LOS. In addition, future studies combining both microbiota and VOC 
analysis may provide additional information about the exact pathophysiology 
underlying LOS in preterm infants.   
In conclusion, we have shown that in preterm infants with LOS in absence of a CVC, 
fecal VOC profiles differed from matched controls, up to three days prior to clinical 
onset. Discriminative accuracy increased upon focusing on infants with LOS caused 
by the same pathogen. Our findings strengthens the increasing notion that the gut 
may be involved in LOS pathogenesis. Furthermore, early non-invasive selection of 
infants who will develop LOS could provide a window of opportunity for development 
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Figure 1. Flow-chart of participants in the study 
Figure 2. Principal component analysis plot depicting the last produced fecal sample 
prior to t0 of cases with a Staphylococcus epidermidis as causative agent and their 
matched controls, showing the first two principal components, which hold the majority 
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